Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Use of hR3 MaB and radiotherapy in treatment of patients with highly malignant astrocytic tumors, phase III

Next Previous
Trial Profile

Use of hR3 MaB and radiotherapy in treatment of patients with highly malignant astrocytic tumors, phase III

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Oct 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nimotuzumab (Primary)
  • Indications Anaplastic astrocytoma; Glioblastoma; Glioma
  • Focus Biomarker; Registrational; Therapeutic Use
  • Sponsors YM BioSciences

    • Most Recent Events

    • 31 Jul 2013 Status changed from active, no longer recruiting to completed as reported by Cuban Clinical Trial Registry.
    • 02 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
    • 03 Nov 2008 A total of 65 patients (all with glioblastoma) have been enrolled as of the 3rd Nov 2008, according to a YM Biosciences media release
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top